|Bid||0.00 x 800|
|Ask||138.10 x 800|
|Day's Range||135.74 - 137.01|
|52 Week Range||118.62 - 148.99|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||24.37|
|Earnings Date||Apr 16, 2019|
|Forward Dividend & Yield||3.60 (2.61%)|
|1y Target Est||144.71|
In the latest trading session, Johnson & Johnson (JNJ) closed at $136.61, marking a -0.22% move from the previous day.
The Oklahoma Supreme Court's decision was a win for the state's attorney general, whose case is set to be the first to face trial of roughly 2,000 lawsuits nationally seeking to hold opioid manufacturers responsible for contributing to the epidemic. Oklahoma Attorney General Mike Hunter's 2017 lawsuit accuses Purdue, Johnson & Johnson & Teva Pharmaceutical Industries Ltd of engaging in deceptive marketing that downplayed the risks of addiction associated with opioid pain drugs while overstating their benefits. The trial delay bid came as Purdue, owned by members of the wealthy Sackler family, was exploring filing for Chapter 11 bankruptcy protection to address potential liabilities stemming from the lawsuits, people familiar with the matter have told Reuters.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
Johnson & Johnson’s (NYSE: JNJ ) bottom line continues to be come under pressure from forex and generic competition, and the company faces sentiment-related headwinds, according to Raymond James. These ...
Johnson & Johnson and Bayer agreed Monday to pay $775 million to settle almost 25,000 lawsuits in connection to blood thinner Xarelto.
Europe suffered a fourth day of losses as persistent worries about the pace of global growth and Brexit uncertainty took their toll on shares in the region. The pan-European STOXX 600 index closed 0.45 percent lower and is now nearly 3 percent lower than the six-month peak reached on March 19. European stocks pulled back from an initial 0.8 percent fall after an unexpected rise in German business sentiment that eased fears of a recession in the European Union's largest economy.
NEW ORLEANS, March 25, 2019 /PRNewswire/ -- The makers of the popular blood thinner Xarelto® have reached a $775 million settlement to resolve litigation filed by patients who suffered a bleeding injury after taking the prescription drug. According to the agreement announced earlier today between plaintiff lawyer leadership and Bayer Healthcare (BAYRY) and Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson (JNJ), the settlement is a private agreement intended to resolve the entire litigation including cases in federal and state courts. "This is a fair and just resolution for thousands of consumers who have substantial claims," says Andy Birchfield of the Beasley Allen law firm and co-lead counsel of the Plaintiffs' Steering Committee for the federal multidistrict litigation.
Bayer and J&J do not admit liability under the agreement. Bayer in a statement on Monday said it continues to believe the claims are without merit. Lawsuits over Xarelto began piling up in 2014 and the companies had so far won all six trials over Xarelto's alleged bleeding risk.
Bayer and J&J do not admit liability under the agreement. The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs. Bayer in a statement on Monday said it continues to believe the claims are without merit.
Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits alleging that their blockbuster blood thinner Xarelto caused unstoppable and in some cases fatal bleeding for a total of $775 million, court documents on Monday showed. Bayer and J&J do not admit liability under the agreement. The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed caused uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of patients.
J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.
- Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion - This is the fourth consecutive quarterly record -- longest streak in the 20 years SPDJI has tracked - Total 2018 buybacks ...
Moody's Investors Service has assigned a Baa2 long-term issuer rating to Alcon Inc. ("Alcon" or "the company"). This is the first time that Moody's assigned ratings to Alcon, a global manufacturer of eye care medical equipment and products which is being spun off from Novartis AG (Novartis, A1 stable).
Long-term income investors know that finding dividend stocks with decades of interrupted payments is only part of the winning formula for income investing. Dividend growth matters, too - which is exactly why investors cherish the Dividend Aristocrats.Dividend Aristocrats are companies in the Standard & Poor's 500-stock index that have hiked their dividends every year for at least 25 consecutive years. Rising dividends naturally make these stocks more attractive to new income investors, and steady payout hikes reward existing investors with increasingly higher yields on their shares' original buy-in cost.Most importantly, regular dividend hikes fuel the magic of compounding. Indeed, many of the best stocks of all time have long histories of dividend growth.Since reliable dividend stocks with growing payouts can provide some comfort amid market uncertainty, we took a look at the 11 Dividend Aristocrats with the longest histories of annual dividend increases. After all, when a dividend stock manages to raise its payout through good times and bad, decade after decade, you know management is making its income-reliant shareholders a top priority. SEE ALSO: The Kiplinger Dividend 15: Our Favorite Dividend-Paying Stocks
(Reuters) - Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million (£536.4 million) impairment charge ...
Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million impairment charge in the first quarter of ...
"We don't need to worry about more rate hikes—and that's why it's causing a sea change in the stock market right now because we're in a low growth environment again," CNBC's Jim Cramer says. Cramer explains what stocks are good to buy in a low-growth environment and which stocks to stay away from. Investors need not worry that the Federal Reserve induced a market "sea change" by calling off interest rate increases this year and adjust their game plan to make money, CNBC's Jim Cramer said Thursday.
It's become increasingly clear over the past few months that Apple (NASDAQ:AAPL) can no longer rely on the iPhone alone. That realization initially tanked Apple stock, which dropped nearly 40% between early October and late December. Of late, however, investors have become more comfortable with that pivot: AAPL stock already has gained nearly 20% so far in 2019.Source: Shutterstock The bull case for Apple stock, as Luke Lango argued this month, is that services revenue can offset hardware pressure. With Apple stock still cheap (it trades at less than 15x forward earnings), even modest growth is enough.Add in the fact that Apple still has more cash on its balance sheet than any company in history, and it doesn't take smashing success for AAPL to move higher.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe bear case, which I laid out in detail last year, is that the iPhone simply is too important. The product still drives 60% of revenue. And with Apple's market capitalization nearly $900 billion, what would be a hit for another company barely moves the needle for Apple. * 7 Beaten-Up Stocks to Buy as They Reverse Course The Apple Watch is an interesting microcosm of that bull/bear debate. And news this week of a landmark study involving the product adds an intriguing layer to the argument.From one standpoint, the Apple Watch could be a key part of the transformation of Apple and AAPL stock. From another, it hardly matters at all. The Apple Watch StudyOn Monday, researchers from Apple and Stanford Medicine released the results of a massive study involving the Apple Watch. Some 419,000 subjects participated over eight months. Those individuals wore the target smartwatches with the capability to detect abnormal heartbeats.The results aren't conclusive. Roughly 0.5% of the participants received notice of an irregular pattern. Unsurprisingly, the rate was higher in older patients.Of those who received a notice, only about 20% followed up by wearing a patch to confirm the diagnosis. Of that group, 34% received a confirmed diagnosis. But in a smaller group of subjects who wore both a patch and the Apple Watch, 84% of atrial fibrillation cases detected by the path were also picked up by the Watch.On the whole, the study does seem like good news for Apple (and for patients). There are concerns about false positives from the technology. However, the innovation is constantly improving and will benefit from further tweaking. As one cardiologist told CNBC, the results were "moderately good for a screening tool, but not amazing." That description could change over time, and more studies should give a better understanding of just how effective the Apple Watch is.The study doesn't prove that the Apple Watch can be a successful cardiac screening tool, at least not yet. A two-in-three false positive rate might be too problematic for some (or most) doctors. But at the least, the study does show that Apple might be on the right path in terms of developing life-saving -- and profitable -- technology. Does It Matter for AAPL Stock?From an investment standpoint, the question is whether even success here is enough. Again, this is a nearly $900 billion company. Fitbit (NYSE:FIT), whose smartwatch category the Apple Watch has taken over, has an enterprise value well under $1 billion.Apple hasn't broken out its smartwatch revenue. But sales of "other products" -- including Apple Watch, AirPods, Apple TV, Beats and other smaller lines -- in fiscal year 2018 were $17.4 billion, according to the 10-K. CFO Luca Maestri last year said AirPods and Apple Watch combined were driving over $10 billion annually in revenue.That's a big number. But the revenue from other products (now called "Wearables, Home and Accessories") still is about 7% of trailing-twelve-month revenue after driving 8.7% of first-quarter sales. Assuming its smartwatch revenue is $7-8 billion (roughly half of that category), it still drives maybe 3% of total corporate revenue. Even modest declines in iPhone revenue will more than offset growth in the Apple Watch. The Services Case for Apple StockSo it's easy perhaps to argue that the smartwatch division simply isn't enough. But where the story gets interesting is not just in hardware sales, but how the company can monetize the services side of the product. Healthcare giant Johnson & Johnson (NYSE:JNJ) is joining in the next controlled study of the Apple Watch. And the product itself could be the tip of the spear in the company's healthcare strategy.Back in January, Dana Blankenhorn detailed that strategy and the ways in which AAPL stock could profit from healthcare services. Monitoring revenues could be large. DexCom (NASDAQ:DXCM) is a $13 billion company built off the back of a continuous glucose monitoring system for diabetes. Other tech giants, including Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), are looking to profit from the intersection of medicine and technology. However, the Apple Watch puts the company into millions of homes, a huge head start.I still question whether it's enough. Even the development of a DexCom-sized business adds less than 2% to Apple's market capitalization. But combined with efforts elsewhere in services, in content, and through share buybacks, there's an argument that Apple can keep profits intact in the near-term before eventually driving growth again.That's the strategy needed to keep AAPL stock moving higher, particularly with the year-to-date rally. How investors view the potential of the Apple Watch given recent developments might show how they will view the possibilities of Apple's larger pivot away from its reliance on hardware … and just how successful that strategy is going to be.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Specialty Retail ETFs to Buy the Industry's Disruption * 5 Stocks To Buy for the Happiest Employees * 3 Out-of-Favor Consumer Stocks to Buy Compare Brokers The post Here's What the Apple Watch Means for AAPL Stock appeared first on InvestorPlace.
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.